# Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Robert L. Coleman,Mark F. Brady,Thomas J. Herzog,Paul Sabbatini,Deborah K. Armstrong,Joan L. Walker,Byoung‐Gie Kim,Keiichi Fujiwara,Krishnansu S. Tewari,David M. O’Malley,Susan A. Davidson,Stephen C. Rubin,Paul DiSilvestro,Karen Basen‐Engquist,Helen Huang,John K. Chan,Nick M. Spirtos,Raheela Ashfaq,Robert S. Mannel |
| Citations | 608 |
| DOI | 10.1016/s1470-2045(17)30279-6 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://escholarship.org/uc/item/8zh4r761 |
| OpenAlex ID | https://openalex.org/W2605456582 |
| PMID | 28438473 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Robert L. Coleman](https://scholariq.org/researchers/robert-l-coleman/)
- [Paul DiSilvestro](https://scholariq.org/researchers/paul-disilvestro/)
- [David M. O’Malley](https://scholariq.org/researchers/david-m-o-malley/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)

## Paper topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.